Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

Authors:
  • CCCalvin Cohen
    Calvin Cohen
  • JGJoseph Gathe
    Joseph Gathe
  • PSPeter Shalit
    Peter Shalit
  • THTrevor Hawkins
    Trevor Hawkins
  • HLHui C. Liu
    Hui C. Liu
  • AMAnita A. Mathias
    Anita A. Mathias
  • SCSteven L. Chuck
    Steven L. Chuck
  • BKBrian P. Kearney
    Brian P. Kearney
  • DWDavid R. Warren
    David R. Warren

Abstract
To assess efficacy and safety of cobicistat versus ritonavir as pharmacoenhancers for atazanavir when administered with emtricitabine/tenofovir df as initial treatment for HIV-1 infection. Randomized, partially placebo-controlled, double-blind, multicenter study. Antiretroviral treatment-naive adults, screening HIV-1 RNA of at least 5000 copies/ml and CD4 cell count more than 50 cells/μl. Randomized 2 : 1 (stratified by HIV RNA ≤ or >100 000 copies/ml) to receive placebo-blinded once-daily cobicistat 150 mg or ritonavir 100 mg with open-label atazanavir and fixed-dose emtricitabine/tenofovir df. Efficacy and safety at weeks 24 and 48. Eighty-four percent of ATV/co participants and 86% of ATV/r participants suppressed HIV-1 RNA (<50 copies/ ml) at week 24, and 82 and 86% at week 48, respectively, and mean CD4 cell count increased 203 and 199 cells/μl at week 24 and 208 and 177 cells/μl at week 48, respectively. Study treatment discontinuation due to adverse events occurred in 4% ATV/co and in 3% ATV/r participants through 48 weeks. Treatment-related adverse events occurred in 36% ATV/co and 48% ATV/r participants; hyperbilirubinemia occurred in 96 and 100%, and ocular icterus or jaundice occurred in 14 and 17%, respectively. Mean estimated glomerular filtration rate (Cockcroft–Gault, ml/min) decrease occurred in both treatment groups and was evident at week 2 (ATV/co −9, ATV/r −4), reached a nadir by week 24 (−15, −14, respectively), and did not progress further through week 48 (−13, −14). Using cobicistat and ritonavir as pharmacoenhancers for atazanavir and administered with emtricitabine/tenofovir df achieved comparable rates of virologic suppression and CD4 cell count increase with satisfactory safety profiles.

This publication has 9 references indexed in Scilit: